Navigation Links
C. Erec Stebbins awarded prestigious EUREKA grant
Date:9/3/2008

C. Erec Stebbins, associate professor at The Rockefeller University, has been awarded an inaugural EUREKA grant from the National Institutes of Health for a project aimed at exploiting a bacteria-based "nanosyringe" as a means of delivering proteins into specific cells for therapeutic purposes. The award, which provides $200,000 a year for three years, was announced by the NIH September 3.

The EUREKA program Exceptional, Unconventional Research Enabling Knowledge Acceleration was established last year to help researchers test novel hypotheses or approach major methodological challenges in projects generally considered too risky for traditional funding vehicles. It is led by the National Institute of General Medical Sciences (NIGMS) with support from the National Institute of Neurological Disorders and Stroke, the National Institute of Mental Health and the National Institute on Drug Abuse. Grant applications were reviewed last fall on several criteria including significance of the problem to be solved, innovation in solving it, logic of the experimental plan and investigator's research history. Unlike conventional grants, however, the EUREKA program does not emphasize the likelihood of a project to produce marketable results. The program awarded a total $42.2 million to 38 scientists.

Stebbins, head of Rockefeller University's Laboratory of Structural Microbiology, studies pathogen-host interactions. In his EUREKA-funded project, Stebbins is examining a molecular tool evolved by pathogenic bacteria that harnesses host energy reserves and precisely delivers toxins into healthy host cells. Stebbins aims to reverse-engineer such a "nanosyringe" for therapeutic use injecting into diseased cells functional versions of proteins that the disease has rendered nonfunctional or proteins that inhibit the action of other, malfunctioning proteins. Clinical applications of the tool include restoring tumor-suppressing proteins or pro-apoptotic polypeptide
'/>"/>

Contact: Joseph Bonner
bonnerj@rockefeller.edu
212-327-8998
Rockefeller University
Source:Eurekalert

Page: 1 2

Related biology news :

1. 12 McGill researchers awarded Canada Research Chairs
2. Anthony S. Fauci awarded Lasker Award for Public Service
3. ETH Zurich professor Ari Helenius awarded Benoist Prize
4. Nanobiosym awarded $2 million DTRA contract
5. Mustafa alAbsi Ph.D. and national team awarded major NIH grant
6. Parus Interactive Awarded Patent for Speech-Activated Remote System Management
7. $2.7 million awarded for metastatic colon cancer research
8. UCR researchers awarded nearly $1.7M to develop improved cowpea varieties
9. BIO-key(R) and Tiger IT Awarded a Follow-on Contract for Nationwide Voter / Citizen Registration in Bangladesh
10. University awarded £5M to investigate how cells communicate
11. Manomet Center awarded major NFWF grant to foster shorebird conservation

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)...lt that occurred during the 2008-09 austral summer...es for two main climate drivers, ENSO (El Nio - So...nnular Mode), according to Dr. Marco Tedesco, Assi... The City College of New York. , Professor Ted...UNY Graduate Center, added that Antarctic snowmelt...
(Date:12/2/2009)...en the evidence that people who smoke cigarettes o...or developing colorectal cancer, even after adjust...e more reason not to smoke, or to quit as soon as ...., M.S., vice president emeritus, epidemiology and...ety. "Colorectal cancer should be added to the lis...
(Date:12/2/2009)...ts exposed to cigarette smoking scenes in movies a...d this may be part of the acculturation process as... study findings. , "Our study supports an R-rati... the global implementation of the World Health Org... which includes guidelines for countries to restri...
Breaking Biology News(10 mins):CCNY professor foresees rising Antarctic snowmelt 2Cigarette smoking increases colorectal cancer risk 2Watching movies featuring characters who smoke negatively influences Mexican-American teens 2Inverness Medical Innovations Declares Dividend on its Series B Convertible Perpetual Preferred Stock 56236 1Blue Shield of California Streamlines Access to Benefits and Prescriptions for Wildfire Victims 56231 1Blue Shield of California Streamlines Access to Benefits and Prescriptions for Wildfire Victims 56231 2Anthem Life 26 Disability Insurance Company offers The Healing Book to Help Young Life Insurance Beneficiaries Cope with the Loss of a Loved One 56226 1Anthem Life 26 Disability Insurance Company offers The Healing Book to Help Young Life Insurance Beneficiaries Cope with the Loss of a Loved One 56226 2
...hat children of women who smoke during pregnancy c... the first time, researchers believe they have evi...prit, but also shows what the substance does to th...ing rats, Raju Metherate, associate professor of n...rvine, showed that nicotine exposure during the eq...
...e to protect the testes of cancer patients against...cientist told the 22nd annual conference of the Eu...y in Prague, Czech Republic on Tuesday 20 June 200...mat Gan, Israel, said that his work showed for the...nces the immune system could protect the testis fr...
...ell known for his care of and research into multip...s can affect a woman,s chances of having twins, an...nation of diet and heredity. By comparing the twin...oducts, with that of women who do eat animal produ...n at Long Island Jewish (LIJ) Medical Center in Ne...
Other Biology News:Nicotine exposure during development leads to hearing problems 2Nicotine exposure during development leads to hearing problems 3Injection may prevent infertility in men receiving cancer chemotherapy 2Study finds that a woman's chances of having twins can be modified by diet 2Study finds that a woman's chances of having twins can be modified by diet 3
(Date:12/2/2009)... Dec. 2 S*BIO Pte Ltd today announ...bitor, SB1518, at The American Society of Hematolo...ns. ,, Data will be presented on the clinical r...B1518 detailing its safety, tolerability and pharm... levels ranging from 100 to 600 mg. These doses we...
(Date:12/2/2009)... Dec. 2 /PRNewswire-Asia/ -- The world is going th...and uncertainty is part of many,businesses and ind... been,relatively immune to the economic downturn, ... During the midst of the difficult times this yea...inaugurated an R&D center in Shanghai, the lar...
(Date:12/1/2009)...Nev., Dec. 1 PDL BioPhar...venue guidance for the fourth quarter ended Decemb...red with $69 million for the fourth quarter of 200... first of two installment payments of $12.5 millio...008 results was a one-time $1.8 million payment fr...
(Date:12/1/2009)... Dec. 1 Harvest Technologies Corp....rom the company sponsored 60-patient clinical tria...hennai, India using the company,s BMAC System to t...mb Ischemia (CLI). Sri Ramachandra Medical Center ...itution based in Chennai, India and one of the lar...
Breaking Biology Technology:S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 2PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 3Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia 2Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia 3
...ted Oral Presentation by Dr. John St. John -, - ...ticle Technology -, ADDISON, Texas, May 28 ULURU...coming 8th World Biomaterials Congress, to be,held...ohn St. John, ULURU,s,Vice President of Material S...ng with the presentation of three posters., The t...
...nbark Provides Additional Global Corporate Finance...ng Experience -, SAN DIEGO, May 28 Nventa Biopha...y the appointment of Gordon H.,Busenbark to the co...y,serves as the chief financial officer of Xytis P... specialty pharmaceuticals company focused on,dise...
...Abstracts Accepted for Presentation at ASCO, SOUT...sdaq: EXEL ) will hold an investor and analyst br... of the American Society of,Clinical Oncology (ASC...2,2008., Participants: -- George A. Scangos, Ph...el M. Morrissey, PhD, President of Research and De...
Other Biology Technology:ULURU Inc. to Present at the 8th World Biomaterials Congress 2ULURU Inc. to Present at the 8th World Biomaterials Congress 3Nventa Appoints Gordon H. Busenbark to Board of Directors 2REMINDER: Exelixis Will Webcast Its June 2 Investor and Analyst Briefing at ASCO 2REMINDER: Exelixis Will Webcast Its June 2 Investor and Analyst Briefing at ASCO 3REMINDER: Exelixis Will Webcast Its June 2 Investor and Analyst Briefing at ASCO 4
Rat Serum Non-Sterile Non-Hemolyzed from Pel-Freez Biologicals
DTNB from Cayman Chemical
...500 V, 400 mA, 200 W maximum.Constant voltage, con...ramp modes.Linear voltage ramp mode brings protein...hout danger of overheating.Volt-hour and milliampe...ckness, sample ionic strength, and temperature.Sto...
Mouse Anti-Bovine CD335 Monoclonal Antibody, ALEXA FLUOR 488 Conjugated, Clone AKS1 from AbD Serotec
Biology Products: